These findings have led to the development of small-molecule– and antibody-based targeted therapies that have either entered the clinic or are currently undergoing clinical trials, including the use of trastuzumab to treat HER2-positive breast cancer [10]. Here, ERBB2 is linked to breast carcinoma.